Executive Order Directs CDC to Reduce Number of Recommended Childhood Vaccines
On May 29, 2026, President Trump signed an executive order titled “Realigning United States Core Childhood Vaccine Recommendations With Best Practices from Peer, Developed Countries” endorsing a scientific assessment done earlier this year by the U.S. Department of Health and Human Services (DHHS) calling for a reduction in the number of recommended vaccines for children […]
CDC Changes Recommendations for Six Childhood Vaccines
The U.S. Department of Health and Human Services (DHHS) announced updates to the national childhood vaccine schedule involving six vaccines (rotavirus, COVID-19, influenza, meningococcal disease, hepatitis A, and hepatitis B) following a presidential memorandum directing the U.S. Centers for Disease Control and Prevention (CDC) to review and revise its recommendations. The changes clarify which vaccines […]
Sanofi Reports Decline in Flu Vaccine Sales
Sanofi SA reported a decline in vaccine sales for the third quarter of 2025, citing reduced vaccination rates and increased pricing competition in Europe and the United States. The company’s legacy vaccine business dropped nearly eight percent to €3.36 billion (US$3.9 billion), while influenza and COVID-19 shot sales fell 17 percent to €1.53 billion (US$1.78 […]
Withheld: Real-World Infant Deaths from RSV Antibody Shot
As ACIP deliberated without access to full trial data, an even more alarming pattern was already unfolding in the real world. Now, analysis of the FDA’s FAERS database reveals 37 infant deaths out of just 991 reports—a fatality signal nearly twice that of other routine vaccines. Why was this not disclosed? The warning sign was […]
ACIP Majority Ignores Risks and Recommends Infants Get Merck’s RSV Monoclonal Antibody
On June 25, 2025, the majority of members of the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) ignored risk warnings and voted for a recommendation that infants be given Merck & Co.’s monoclonal antibody, clesrovimab, marketed as Enflonsia. The committee advised using Enflonsia to prevent Respiratory Syncytial Virus […]
Moderna Withdraws Application for Combination COVID and Flu Vaccine
Moderna, Inc. withdrew its application for United States licensure for its combination COVID-19/Influenza vaccine known as mRNA-1083. The company stated the decision came “in consultation with” the U.S. Food and Drug Administration (FDA).1 The decision came just one day after the FDA announced the agency would require new clinical trials for approval of annual COVID […]